Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 11, 2022

BUY
$0.69 - $1.21 $345,000 - $605,000
500,000 Added 14.29%
4,000,000 $3.85 Million
Q1 2022

May 12, 2022

BUY
$1.02 - $3.8 $510,000 - $1.9 Million
500,000 Added 16.67%
3,500,000 $4.17 Million
Q4 2021

Feb 11, 2022

BUY
$3.26 - $4.66 $3.26 Million - $4.66 Million
1,000,000 Added 50.0%
3,000,000 $9.78 Million
Q3 2021

Nov 12, 2021

BUY
$4.08 - $5.66 $1.22 Million - $1.7 Million
300,000 Added 17.65%
2,000,000 $8.94 Million
Q2 2021

Aug 13, 2021

BUY
$5.01 - $7.48 $3.38 Million - $5.05 Million
675,000 Added 65.85%
1,700,000 $9.27 Million
Q1 2021

May 14, 2021

BUY
$7.19 - $14.95 $1.98 Million - $4.11 Million
275,000 Added 36.67%
1,025,000 $7.67 Million
Q4 2020

Feb 11, 2021

BUY
$6.66 - $14.66 $1.89 Million - $4.17 Million
284,500 Added 61.12%
750,000 $8.14 Million
Q3 2020

Nov 13, 2020

SELL
$8.69 - $14.47 $212,905 - $354,515
-24,500 Reduced 5.0%
465,500 $4.12 Million
Q2 2020

Aug 14, 2020

SELL
$5.21 - $11.03 $84,078 - $178,002
-16,138 Reduced 3.19%
490,000 $5.22 Million
Q1 2020

May 14, 2020

BUY
$4.46 - $9.2 $2.26 Million - $4.66 Million
506,138 New
506,138 $3 Million

About Syros Pharmaceuticals, Inc.


  • Ticker SYRS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 20,236,200
  • Market Cap $4.05M
  • Description
  • Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically def...
More about SYRS
Track This Portfolio

Track Artal Group S.A. Portfolio

Follow Artal Group S.A. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

News

Stay updated on Artal Group S.A. with notifications on news.